Table 5 Dental developmental anomalies and DMFT (decayed, missing, and filled teeth) in childhood cancer survivors, according to chemotherapy agents, classified into 8 groups.
Classification | ATG N = 25 | Alkylating Agent N = 98 | DNA Crosslinking Agents N = 43 | Antimetabolite N = 53 | Topoisomerase 2 Inhibitors N = 67 | Hormonal Agents N = 36 | Tubulin Inhibitors N = 67 | Miscellaneous N = 41 |
|---|---|---|---|---|---|---|---|---|
Drugs | Anti-thymocyte globolin | Busulfan Melphalan Treosulfan Cyclophosphamide Dacarbazine Temozolomide Thiotepa Ifosfamide Mitomycin-C Dactinomycin Cytoxan | Fludarabine Cisplatin Thiotepa Melphalan Carboplatin | 5-Fluorouracil 6-Mercaptopurine Capecitabine Cytarabine Floxuridine Fludarabine Gemcitabine Hydroxycarbamide Methotrexate Pemetrexed Cytosar-U Thioguanine | VP16, Doxorubicin Irinotecan Daunorubicin Mitoxantrone Esroubicin Teniposide Amsacrine Topotecan | Tamoxifen Aromatase inhibitors Androgens High doses estrogen | Colchicine vinblastine vincristine vinorelbine halichondrins | Aspaginase Aclacinomycin Streptozocin Menogaril Actinomycin Bleomycin ATRA Bleomycin Imatinib Desatimb Brentuximab |
Any malformed teeth | 11 (44%) | 44 (45%) | 23 (53%) | 25 (47%) | 32 (48%) | 19 (53%) | 32 (48%) | 19 (46%) |
Type of Malformation (> 1 tooth with malformation) | ||||||||
Hypocalcification or Hypoplasia) | 3 (12%) | 16 (16%) | 11 (26%) | 8 (15%) | 12 (18%) | 5 (14%) | 13 (19%) | 5 (12%) |
Microdontia | 4 (16%) | 17 (17%) | 8 (19%) | 11 (21%) | 14 (21%) | 9 (25%) | 14 (21%) | 8 (20%) |
Root change | 4 (16%) | 21 (21%) | 9 (21%) | 11 (21%) | 16 (24%) | 11 (31%) | 17 (25%) | 10 (24%) |
Hypodontia | 4 (16%) | 11 (11%) | 6 (14%) | 3 (6%) | 7 (10%) | 2 (6%) | 6 (9%) | 2 (5) |
DMFT | 6.12 (6.37) | 6.31 (6.23) | 7 (5.99) | 6.53 (6.88) | 5.85 (5.69) | 6.94 (6.01) | 6.99 (6.27) | 6.54 (6.87) |
Total number of malformed teeth | 2.4 (5.73) | 2.55 (5.43) | 3.42 (6.96) | 2.17 (4.09) | 2.37 (4.50) | 2.31 (3.21) | 2.99 (5.58) | 2.61 (5.09) |
